Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Perrigo Company    PRGO

Financials ($)
Sales 2017 4 812 M
EBIT 2017 946 M
Net income 2017 351 M
Debt 2017 2 679 M
Yield 2017 0,79%
Sales 2018 4 937 M
EBIT 2018 1 006 M
Net income 2018 480 M
Debt 2018 2 081 M
Yield 2018 0,82%
P/E ratio 2017 34,51
P/E ratio 2018 24,05
EV / Sales2017 3,08x
EV / Sales2018 2,88x
Capitalization 12 128 M
More Financials
Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products.It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences.The CHC segment includes... 
10/26Earnings Release
More about the company
Surperformance© ratings of Perrigo Company
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY
09/21 PERRIGO : Announces FDA Final Approval For Its AB Rated Generic Version Of Exalg..
09/18 PERRIGO : Announces Tentative FDA Approval For The Generic Version Of Acanya® Ge..
08/30 PERRIGO : To Present At Upcoming Investor Conferences
08/23 FDA APPROVES PERRIGO COMPANY PLC. (N : PRGO) Generic Version of AstraZeneca plc...
08/23 PERRIGO COMPANY PLC : ex-dividend day
08/21 PERRIGO : Announces Final FDA Approval And Settlement For The Store Brand OTC Eq..
08/21 PERRIGO COMPANY PLC : Earnings Review and Free Research Report: Perrigo Reported..
08/17 PERRIGO : Announces FDA Final Approval for its AB Rated Generic Version of Mycol..
08/16 PERRIGO : Announces FDA Final Approval for its AB Rated Generic Version of Mycol..
08/11 PERRIGO COMPANY PLC ORDINARY SHARES : PRGO) To Sell Its Active Pharma Business ..
More news
Sector news : Pharmaceuticals - NEC
09/22DJCorrection to Sept. 7 Harvey Rebuilding Article
09/22 Korea tensions keep European shares in check before Germany vote
09/22 Bettencourt death stirs speculation about L'Oreal ownership
09/22 China online insurer ZhongAn prices Hong Kong IPO at top end, raises $1.5 bil..
09/21DJPFIZER : Files Antitrust Lawsuit Against J&J -- WSJ
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 18
Average target price 81,5 $
Spread / Average Target -4,2%
EPS Revisions
John T. Hendrickson Chief Executive Officer & Director
Mary Lauren Brlas Chairman
Ron L. Winowiecki Chief Financial Officer
Thomas Farrington Chief Information Officer & Executive VP
Grainne Quinn Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.63%353 617
NOVARTIS11.88%223 850
ROCHE HOLDING LTD.6.19%221 926
PFIZER10.81%214 206
MERCK AND COMPANY11.75%178 914